CTXR - Citius Pharmaceuticals, Inc. -  [ ]

Seasonality of Returns By Period

Average daily return by calendar bucket (ClosePriceSA).

Day of Week

Week of Month

Month of Year

Seasonal Path

YTD vs Last Year vs Lookback Avg · closes rebased to 100 at each year's first session
Ticker Details
Citius Pharmaceuticals, Inc.
Citius Pharmaceuticals Inc is a specialty pharmaceutical company engaged in development and commercialization of therapeutic products for markets using patented or proprietary formulations and modified drug delivery technology.
IPO Date: June 9, 2017
Sector: Healthcare
Industry: Biotech
Market Cap: $13.76M
Activated in VL: True
Average Daily Range
Avg Daily Range: $0.08 | 5.20%
Avg Daily Range (30 D): $0.02 | 2.92%
Avg Daily Range (90 D): $0.03 | 5.01%
Institutional Daily Volume
Avg Daily Volume: 1.58M
Avg Daily Volume (30 D): .21M
Avg Daily Volume (90 D): .39M
Trade Size
Avg Trade Size (Sh.): 417
Avg Trade Size (Sh.) (30 D): 374
Avg Trade Size (Sh.) (90 D): 373
Institutional Trades
Total Institutional Trades: 45
Avg Institutional Trade: $2.78M
Avg Institutional Trade (30 D): $6.8M
Avg Institutional Trade (90 D): $6.8M
Avg Institutional Trade Volume: .06M
Avg Institutional Trades (Per Day): 1
Market Closing Trades
Avg Closing Trade: $6.35M
Avg Closing Trade (30 D): $6.8M
Avg Closing Trade (90 D): $6.8M
Avg Closing Volume: 149.91K
 
News
Feb 13, 2026 @ 1:00 PM
Citius Pharmaceuticals, Inc. Announces First Repor...
Source: Prnewswire
Feb 13, 2026 @ 1:00 PM
Citius Oncology, Inc. Announces First Reported Rev...
Source: Prnewswire
Dec 24, 2025 @ 2:04 PM
Stock Market Today: Dow Jones, Nasdaq Futures Slip...
Source: Rishabh Mishra
Dec 10, 2025 @ 9:30 PM
Citius Oncology Announces Closing of $18 Million C...
Source: Prnewswire
Dec 9, 2025 @ 1:30 PM
Citius Oncology Announces $18 Million Concurrent R...
Source: Prnewswire
Financials
  TTM Q2 2026 Q1 2026
Basic EPS $-.34 $-.95 $-.38
Diluted EPS $-.34 $-.95 $-.38
Revenue $1.49M $1.67M $3.94M
Gross Profit $1M $1.34M $3.15M
Net Income / Loss $-11.92M $-28.11M $-9.39M
Operating Income / Loss $-11.73M $-32.19M $-9.02M
Cost of Revenue $.49M $.33M $.79M
Net Cash Flow $12.42M $-3.13M $3.47M
PE Ratio    
Splits
Nov 26, 2024 1:25
Jun 09, 2017 1:15
Sep 12, 2014 5:8